

Gilead declares Mylan as exclusive branded medicine partner

05 February 2014 | News | By BioSpectrum Bureau

Gilead declares Mylan as exclusive branded medicine partner



GILEAD

Gilead Sciences, announced that Mylan Pharmaceuticals, the Indian-based subsidiary of Mylan Inc, as its exclusive branded medicine business partner for India.

Under the agreement, Mylan will market and distribute in India certain Gilead medications:

- HIV therapies Viread (tenofovir disoproxil fumarate), Truvada (emtricitabine/tenofovir disoproxil fumarate) and the newer single tablet regimen Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)

- AmBisome (amphotericin B liposome for injection), a treatment for life-threatening, systemic fungal infections, which is also used to treat the parasitic disease visceral leishmaniasis

- Viread for its indication as a treatment for chronic hepatitis B virus (HBV) infection.

"The appointment of Mylan as our branded medicine business partner in India is a result of their strong knowledge of the Indian healthcare system and demonstrated capabilities of supporting and distributing antiretroviral therapies," said Mr Gregg H Alton, Gilead's executive vice president of Corporate and Medical Affairs.

In addition to distributing branded Gilead medicines, Mylan will manage regulatory and pharma co-vigilance activities (such as adverse event reporting) as well as broader medical education initiatives.